Information Provided By:
Fly News Breaks for June 26, 2017
MDXG
Jun 26, 2017 | 09:30 EDT
Needham analyst Mike Matson raised his price target on MiMedx to $20 from $15 as he expects the upcoming top line data from the company's diabetic foot ulcer and venous leg ulcer to drive more doctors to use and more insurers to cover EpiFix. He keeps a Strong Buy rating on the stock.